Treatment of Multiple Sclerosis

Trial Design, Results, and Future Perspectives

  • Richard A. Rudick
  • Donald E. Goodkin

Part of the Clinical Medicine and the Nervous System book series (CLIN.MED.NERV.)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Donald E. Goodkin
    Pages 17-45
  3. Donald Paty, Ernest Willoughby, John Whitaker
    Pages 47-90
  4. Richard A. C. Hughes
    Pages 157-172
  5. Murray B. Bornstein, Kenneth P. Johnson
    Pages 173-198
  6. Glenn A. Mackin, David M. Dawson, David A. Hafler, Howard L. Weiner
    Pages 199-216
  7. Jerry S. Wolinsky
    Pages 217-232
  8. Lawrence Jacobs, Frederick Munschauer
    Pages 233-250
  9. John H. Noseworthy
    Pages 251-266
  10. Stuart D. Cook, Corinne Devereux, Raymond Troiano, Christine Rohowsky-Kochan, Amiram Sheffet, Annette Jotkowitz et al.
    Pages 267-279
  11. David A. Hafler, Staley A. Brod, Howard L. Weiner
    Pages 301-307
  12. Back Matter
    Pages 309-313

About this book


Multiple sclerosis is one of the major current problems in neurol­ ogical practice. It remains incompletely understood, yet is a common cause of chronic disability in developed Western so­ cieties: Patients with the disease have difficulty understanding what has happened to them and become bewildered by the con­ trast between the evidently large body of knowledge concerning the clinical manifestations and course of the disease, and the conflicting views they so often receive from different specialists as to the best current management of their disease. As in so many disorders for which treatment is only partially effective, at best, "alternative" therapies abound. Dr. Rudick and Dr. Goodkin have extensive experience in the day-to-day management of multiple sclerosis at the Mellen Center for Multiple Sclerosis Treatment and Research, attached to the Cleveland Clinic. In this book they have assembled a group of experts from several countries and have provided a comprehensive review of the results of different treatments of the disease. Each treatment is considered in the light of its proposed scientific basis or mode of action, and in relation to ethical and trial design issues. This information deserves to be made widely available. As the treatment of multiple sclerosis enters a new era as a result of the new understanding of the cellular mechanisms of demyelination and the molecular biology of the immune response, this information about current treatments assumes additional importance. The book is of interest to all physicians concerned with the management of patients with the disease.


Autoimmunity Clinical trials Multiple Sklerose clinical trial immunotherapy interferon multiple sclerosis myelin research steroids

Editors and affiliations

  • Richard A. Rudick
    • 1
  • Donald E. Goodkin
    • 1
  1. 1.Mellen Center for Multiple Sclerosis Treatment and ResearchCleveland Clinic FoundationClevelandUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag London 1992
  • Publisher Name Springer, London
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4471-3186-1
  • Online ISBN 978-1-4471-3184-7
  • Series Print ISSN 1431-147X
  • Buy this book on publisher's site